Your session is about to expire
← Back to Search
Depemokimab for Asthma (SWIFT-1 Trial)
SWIFT-1 Trial Summary
This trial will test whether GSK3511294 is effective and safe in people with severe uncontrolled asthma that is characterized by high levels of eosinophils.
SWIFT-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SWIFT-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a pre-bronchodilator FEV1 less than 80% predicted.You have, or with high likelihood of having, asthma with an eosinophilic phenotype.You are allergic or intolerant to the ingredients in GSK3511294 or any other similar medications.You have taken certain medications called mepolizumab, reslizumab, or benralizumab in the last year, or you have tried other medications that target a specific protein called IL-5 or its receptor and they didn't work for you.You have certain conditions that can cause high levels of a specific type of white blood cell called eosinophils.You have a documented physician diagnosis of asthma for at least 2 years that meets the National Heart, Lung, and Blood Institute (NHLBI) guidelines or Global Initiative for Asthma (GINA) guidelines.
- Group 1: Participants receiving GSK3511294 (Depemokimab)
- Group 2: Participants receiving placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are a part of this experiment?
"Yes, the information on clinicaltrials.gov suggests that this trial is actively searching for participants. The trial was initially posted on 3/17/2021 and was most recently updated on 10/18/2022. The study is enrolling 375 patients between 33 locations."
What is the margin of safety for GSK3511294 (Depemokimab)?
"GSK3511294 (Depemokimab) has been rated as a 3 in terms of safety. This is due to being a Phase 3 trial, which provides some evidence of efficacy as well as multiple rounds of data supporting its safety."
Are we still enrolling individuals for this clinical research project?
"The website clinicaltrials.gov has the most recent information on this trial, which is actively recruiting patients. The study was created on 3/17/2021 and was last edited on 10/18/2022."
How many locations are conducting this research?
"This study is enrolling at 33 sites, which are situated in and around San Antonio, Houston, and Cypress. Please choose the location most convenient for you to limit travel-related impact on your life if you decide to participate."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- GSK Investigational Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger